237 related articles for article (PubMed ID: 17531931)
1. Effects of "newer" and "older" antihypertensive drugs on hemorrheological, platelet, and endothelial factors. A substudy of the Anglo-Scandinavian Cardiac Outcomes Trial.
Spencer CG; Felmeden DC; Blann AD; Lip GY
Am J Hypertens; 2007 Jun; 20(6):699-704. PubMed ID: 17531931
[TBL] [Abstract][Full Text] [Related]
2. Von Willebrand factor, soluble P-selectin, and target organ damage in hypertension: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT).
Spencer CG; Gurney D; Blann AD; Beevers DG; Lip GY;
Hypertension; 2002 Jul; 40(1):61-6. PubMed ID: 12105139
[TBL] [Abstract][Full Text] [Related]
3. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial.
Dahlöf B; Sever PS; Poulter NR; Wedel H; Beevers DG; Caulfield M; Collins R; Kjeldsen SE; Kristinsson A; McInnes GT; Mehlsen J; Nieminen M; O'Brien E; Ostergren J;
Lancet; 2005 Sep 10-16; 366(9489):895-906. PubMed ID: 16154016
[TBL] [Abstract][Full Text] [Related]
4. Haemorheological, platelet and endothelial indices in relation to global measures of cardiovascular risk in hypertensive patients: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial.
Spencer CG; Felmeden DC; Blann AD; Lip GY
J Intern Med; 2007 Jan; 261(1):82-90. PubMed ID: 17222171
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of plasma soluble P-selectin and von Willebrand factor as indices of platelet activation and endothelial damage/dysfunction in high-risk patients with hypertension: a sub-study of the Anglo-Scandinavian Cardiac Outcomes Trial.
Varughese GI; Patel JV; Tomson J; Blann AD; Hughes EA; Lip GY
J Intern Med; 2007 Apr; 261(4):384-91. PubMed ID: 17391113
[TBL] [Abstract][Full Text] [Related]
6. Relationship of homocysteine to markers of platelet and endothelial activation in "high risk" hypertensives: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial.
Spencer CG; Martin SC; Felmeden DC; Blann AD; Beevers GD; Lip GY
Int J Cardiol; 2004 Apr; 94(2-3):293-300. PubMed ID: 15093996
[TBL] [Abstract][Full Text] [Related]
7. Differences in the magnitude of wave reflection account for differential effects of amlodipine- versus atenolol-based regimens on central blood pressure: an Anglo-Scandinavian Cardiac Outcome Trial substudy.
Manisty CH; Zambanini A; Parker KH; Davies JE; Francis DP; Mayet J; McG Thom SA; Hughes AD;
Hypertension; 2009 Oct; 54(4):724-30. PubMed ID: 19704107
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of Sevikar® compared to the combination of perindopril plus amlodipine on central arterial blood pressure in patients with moderate-to-severe hypertension: Rationale and design of the SEVITENSION study.
Ruilope LM; Schaefer A
Contemp Clin Trials; 2011 Sep; 32(5):710-6. PubMed ID: 21586342
[TBL] [Abstract][Full Text] [Related]
9. Different effect of antihypertensive drugs on conduit artery endothelial function.
Ghiadoni L; Magagna A; Versari D; Kardasz I; Huang Y; Taddei S; Salvetti A
Hypertension; 2003 Jun; 41(6):1281-6. PubMed ID: 12719441
[TBL] [Abstract][Full Text] [Related]
10. Differential effects of antihypertensive treatment on left ventricular diastolic function: an ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial) substudy.
Tapp RJ; Sharp A; Stanton AV; O'Brien E; Chaturvedi N; Poulter NR; Sever PS; Thom SA; Hughes AD; Mayet J;
J Am Coll Cardiol; 2010 Apr; 55(17):1875-81. PubMed ID: 20413040
[TBL] [Abstract][Full Text] [Related]
11. Baseline heart rate, antihypertensive treatment, and prevention of cardiovascular outcomes in ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial).
Poulter NR; Dobson JE; Sever PS; Dahlöf B; Wedel H; Campbell NR;
J Am Coll Cardiol; 2009 Sep; 54(13):1154-61. PubMed ID: 19761936
[TBL] [Abstract][Full Text] [Related]
12. Differential effects of antihypertensive drug therapy on arterial compliance.
Resnick LM; Lester MH
Am J Hypertens; 2002 Dec; 15(12):1096-100. PubMed ID: 12460707
[TBL] [Abstract][Full Text] [Related]
13. Abnormalities of hemorheological, endothelial, and platelet function in patients with chronic heart failure in sinus rhythm: effects of angiotensin-converting enzyme inhibitor and beta-blocker therapy.
Gibbs CR; Blann AD; Watson RD; Lip GY
Circulation; 2001 Apr; 103(13):1746-51. PubMed ID: 11282905
[TBL] [Abstract][Full Text] [Related]
14. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study.
Williams B; Lacy PS; Thom SM; Cruickshank K; Stanton A; Collier D; Hughes AD; Thurston H; O'Rourke M; ; ;
Circulation; 2006 Mar; 113(9):1213-25. PubMed ID: 16476843
[TBL] [Abstract][Full Text] [Related]
15. Beneficial effects of combination therapy with angiotensin II receptor blocker and angiotensin-converting enzyme inhibitor on vascular endothelial function.
Morimoto S; Maki K; Aota Y; Sakuma T; Iwasaka T
Hypertens Res; 2008 Aug; 31(8):1603-10. PubMed ID: 18971536
[TBL] [Abstract][Full Text] [Related]
16. Platelet and haemorheological markers in 'high risk' hypertensives are improved by tighter blood pressure control and cardiovascular risk management: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT).
Spencer CG; Gurney D; Felmeden DC; Blann AD; Beevers DG; Lip GY
J Intern Med; 2004 Jan; 255(1):59-67. PubMed ID: 14687239
[TBL] [Abstract][Full Text] [Related]
17. Effect of hypotensive drugs on the circadian blood pressure pattern in essential hypertension: a comparative study.
Zakopoulos N; Stamatelopoulos S; Moulopoulos S
Cardiovasc Drugs Ther; 1997 Dec; 11(6):795-9. PubMed ID: 9512875
[TBL] [Abstract][Full Text] [Related]
18. The Anglo-Scandinavian Cardiac Outcomes Trial-- blood pressure lowering arm.
Coleman JJ; Kendall MJ
J Clin Pharm Ther; 2006 Aug; 31(4):299-307. PubMed ID: 16882098
[No Abstract] [Full Text] [Related]
19. A comparison of flow-mediated dilatation and von Willebrand factor as markers of endothelial cell function in health and in hypertension: relationship to cardiovascular risk and effects of treatment: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial.
Felmeden DC; Blann AD; Spencer CG; Beevers DG; Lip GY
Blood Coagul Fibrinolysis; 2003 Jul; 14(5):425-31. PubMed ID: 12851527
[TBL] [Abstract][Full Text] [Related]
20. [Old or new antihypertensives--which are better?].
Schrader J; Kulschewski A
MMW Fortschr Med; 2005 Mar; 147(13):36-7, 39-40. PubMed ID: 15832760
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
